Vanguard Group Inc. Trims Holdings in DaVita Inc. $DVA

Vanguard Group Inc. trimmed its holdings in DaVita Inc. (NYSE:DVA) by 10.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,227,904 shares of the company’s stock after selling 519,622 shares during the quarter. Vanguard Group Inc. owned 5.99% of DaVita worth $561,762,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Hantz Financial Services Inc. grew its holdings in DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the period. MAI Capital Management boosted its holdings in DaVita by 23.4% during the second quarter. MAI Capital Management now owns 438 shares of the company’s stock worth $62,000 after buying an additional 83 shares in the last quarter. NewEdge Advisors LLC grew its position in DaVita by 20.8% during the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after buying an additional 88 shares during the period. Teacher Retirement System of Texas grew its position in shares of DaVita by 1.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 6,696 shares of the company’s stock valued at $954,000 after acquiring an additional 94 shares during the period. Finally, Smartleaf Asset Management LLC increased its stake in shares of DaVita by 34.9% in the 3rd quarter. Smartleaf Asset Management LLC now owns 452 shares of the company’s stock valued at $59,000 after purchasing an additional 117 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on DVA shares. Truist Financial set a $158.00 price objective on DaVita in a report on Thursday, February 5th. UBS Group upped their price objective on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Barclays boosted their price target on shares of DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. Finally, Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $155.80.

DaVita Price Performance

NYSE DVA opened at $150.89 on Wednesday. The firm’s fifty day moving average price is $122.00 and its 200 day moving average price is $125.47. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $157.12. The company has a market capitalization of $10.08 billion, a price-to-earnings ratio of 15.23, a price-to-earnings-growth ratio of 0.53 and a beta of 0.99.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The company had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.51 billion. During the same period last year, the firm earned $2.24 EPS. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, sell-side analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.